Clinical Research Directory
Browse clinical research sites, groups, and studies.
Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls
Sponsor: University Hospital, Basel, Switzerland
Summary
The investigator hypothesize that low-dose MDMA (3,4-methylenedioxymethamphetamine) will produce a sufficiently strong oxytocin stimulation in healthy controls and no relevant increase in patients. This study will confirm previously published data and provide important safety data with low-dose MDMA stimulation testing.
Official title: Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency (Central Diabetes Insipidus) and Healthy Controls - the OxyMAX Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2025-01-27
Completion Date
2026-12
Last Updated
2025-02-19
Healthy Volunteers
Yes
Conditions
Interventions
MDMA
MDMA will be administered in a single dose of 50 mg (2 capsules of 25 mg MDMA) or 25mg (1 capsule of 25 mg MDMA, 1 capsule containing only mannitol filler) and given at treatment visit.
Placebo
Placebo will be prepared as identical gelatin capsules containing only mannitol filler and given at treatment visit.
Locations (1)
University Hospital Basel
Basel, Switzerland